Ocumension Therapeutics 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-01-21 6:21 pm Purchase |
2020-12-31 | 13D | EyePoint Pharmaceuticals, Inc. EYPT |
Ocumension Therapeutics | 3,010,722 16.600% |
3,010,722 (New Position) |
Filing |